Based on these observations, our results show that IE-DAP (the specific agonist of NOD1) could weaken the effect of Evo on the suppression of activating NF-κB and MAPK and Evo-induced apoptosis of HCC cells. This evidence concerns the gene NFKB1 and hepatocellular carcinoma.